Of mice and men: Divergent risks of teriparatide-induced osteosarcoma

Osteoporosis International

Volumn 21, Issue 6, 2010, Pages 1041-1045

  Subbiah, V ^a   Madsen, V S ^a   Raymond, A K ^a   Benjamin, R S ^a   Ludwig, J A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Bone cancer; Osteoporosis; Osteosarcoma; Recombinant 1 34 PTH; Sarcoma; Teriparatide

Indexed keywords

PARATHYROID HORMONE[1-34];

AGED; ARTICLE; CASE REPORT; HUMAN; MALE; MOUSE; NONHUMAN; OSTEOPOROSIS; OSTEOSARCOMA; PRIORITY JOURNAL; RADIATION; RAT;

AGED; ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; COCARCINOGENESIS; HUMANS; MALE; NEOPLASMS, RADIATION-INDUCED; OSTEOPOROSIS; OSTEOSARCOMA; RADIOTHERAPY; RATS; TERIPARATIDE;

EID: 77954553687     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-009-1004-0     Document Type: Article

References (13)

1. Services USDoHaH. (U. S. Dept. of Health and Human Services, Office of the Surgeon General). Bone Health and Osteoporosis: A Report of the Surgeon General. 2004.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57 (1):43-66
3. Huvos AG, Butler A, Bretsky SS (1983) Osteogenic sarcoma associated with Paget's disease of bone. A clinicopathologic study of 65 patients. Cancer 52 (8):1489-1495
4. Rosemann M, Kuosaite V, Nathrath M, Atkinson MJ (2002) The genetics of radiation-induced and sporadic osteosarcoma: a unifying theory? J Radiol Prot 22 (3 A): A113-A116
5. Vahle JL, Sato M, Long GG et al (2002) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 30 (3):312-321
6. Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M (2004) Bone neoplasms in F344 rats given teriparatide [rhPTH (1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 32 (34):426-438
7. Harper KD, Krege JH, Marcus R, Mitlak BH (2006) Comments on initial experience with teriparatide in the United States. Curr Med Res Opin 22 (10):1927
8. Harper KD, Krege JH, Marcus R, Mitlak BH (2007) Osteosarcoma and teriparatide? J Bone Miner Res 22 (2):334
9. Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM (2001) Intermittently administered human parathyroid hormone (1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 16 (1):157-165
10. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R (1993) Anabolic actions of parathyroid hormone on bone. Endocr Rev 14 (6):690-709
11. Jolette J, Wilker CE, Smith SY et al (2006) Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats. Toxicol Pathol 34 (7):929-940
12. Divieti P, Geller AI, Suliman G, Juppner H, Bringhurst FR (2005) Receptors specific for the carboxyl-terminal region of parathyroid hormone on bone-derived cells: determinants of ligand binding and bioactivity. Endocrinology 146 (4):1863-1870
13. Tashjian AH, Gagel RF (2006) Teriparatide [human PTH (1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res 21 (3):388-365